[go: up one dir, main page]

RU2018103944A3 - - Google Patents

Download PDF

Info

Publication number
RU2018103944A3
RU2018103944A3 RU2018103944A RU2018103944A RU2018103944A3 RU 2018103944 A3 RU2018103944 A3 RU 2018103944A3 RU 2018103944 A RU2018103944 A RU 2018103944A RU 2018103944 A RU2018103944 A RU 2018103944A RU 2018103944 A3 RU2018103944 A3 RU 2018103944A3
Authority
RU
Russia
Application number
RU2018103944A
Other versions
RU2018103944A (ru
RU2721776C9 (ru
RU2721776C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018103944A publication Critical patent/RU2018103944A/ru
Publication of RU2018103944A3 publication Critical patent/RU2018103944A3/ru
Application granted granted Critical
Publication of RU2721776C2 publication Critical patent/RU2721776C2/ru
Publication of RU2721776C9 publication Critical patent/RU2721776C9/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal (AREA)
RU2018103944A 2015-07-15 2016-07-11 Производные этинила как модуляторы метаботропного рецептора глутамата RU2721776C9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15176854 2015-07-15
EP15176854.6 2015-07-15
PCT/EP2016/066393 WO2017009275A1 (en) 2015-07-15 2016-07-11 Ethynyl derivatives as metabotropic glutamate receptor modulators

Publications (4)

Publication Number Publication Date
RU2018103944A RU2018103944A (ru) 2019-08-16
RU2018103944A3 true RU2018103944A3 (ru) 2019-12-13
RU2721776C2 RU2721776C2 (ru) 2020-05-22
RU2721776C9 RU2721776C9 (ru) 2020-10-22

Family

ID=53758003

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018103944A RU2721776C9 (ru) 2015-07-15 2016-07-11 Производные этинила как модуляторы метаботропного рецептора глутамата

Country Status (30)

Country Link
US (3) US10189848B2 (ru)
EP (1) EP3322701B1 (ru)
JP (1) JP6761821B2 (ru)
KR (1) KR20180026438A (ru)
CN (1) CN107580598B (ru)
AR (1) AR105341A1 (ru)
AU (1) AU2016292863B2 (ru)
CA (1) CA2984711C (ru)
CL (1) CL2018000036A1 (ru)
CO (1) CO2017011174A2 (ru)
CR (1) CR20180022A (ru)
DK (1) DK3322701T3 (ru)
ES (1) ES2733468T3 (ru)
HR (1) HRP20191139T1 (ru)
HU (1) HUE045145T2 (ru)
IL (1) IL255096B (ru)
LT (1) LT3322701T (ru)
MA (1) MA42442B1 (ru)
MX (1) MX374409B (ru)
PE (1) PE20180356A1 (ru)
PH (1) PH12018500106A1 (ru)
PL (1) PL3322701T3 (ru)
PT (1) PT3322701T (ru)
RS (1) RS58929B1 (ru)
RU (1) RU2721776C9 (ru)
SI (1) SI3322701T1 (ru)
TR (1) TR201909160T4 (ru)
TW (1) TWI612962B (ru)
UA (1) UA120463C2 (ru)
WO (1) WO2017009275A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA125503C2 (uk) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
WO2014172644A2 (en) 2013-04-19 2014-10-23 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
UA121669C2 (uk) 2015-02-20 2020-07-10 Інсайт Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
MX374409B (es) 2015-07-15 2025-03-04 Hoffmann La Roche Derivados de etinilo como moduladores del receptor de glutamato metabotrópico.
MA45665B1 (fr) 2016-07-18 2020-11-30 Hoffmann La Roche Dérivés d'éthynyle
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
CN112566912A (zh) 2018-05-04 2021-03-26 因赛特公司 Fgfr抑制剂的盐
JP7633676B2 (ja) 2018-07-26 2025-02-20 ドメイン・セラピューティクス 置換キナゾリノン誘導体、及びmGluR4のポジティブアロステリック調節剤としてのその使用
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4069695A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20250156792A (ko) * 2023-03-10 2025-11-03 브라이트씨드, 인크. 스트레스 조절을 위한 조성물 및 방법 및 이의 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
ZA200709819B (en) 2005-05-24 2009-09-30 Serono Lab Tricyclic spiro derivatives as CRTH2 modulators
MX2009002347A (es) 2006-08-31 2009-03-16 Schering Corp Derivados de hidantoina utiles como agentes antibacterianos.
SG185285A1 (en) 2007-06-03 2012-11-29 Univ Vanderbilt Benzamide mglur5 positive allosteric modulators and methods of making and using same
CA2952055C (en) 2008-02-01 2020-07-21 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Monoclonal antibodies for ebola and marburg viruses
CA2749319C (en) 2009-01-19 2018-02-06 Anna Catania Melanocortin analogs with antimicrobial activity
US9097713B2 (en) 2009-09-02 2015-08-04 The United States Of America As Represented By The Secretary Of The Army On Behalf Of Usamrmc Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus
CA2773038A1 (en) 2009-09-04 2011-03-10 P. Jeffrey Conn Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US8759377B2 (en) 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8586581B2 (en) 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
US8772300B2 (en) 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
HUE025031T2 (en) 2011-04-26 2016-02-29 Hoffmann La Roche Ethinyl derivatives as positive allosteric modulators of MGLUR5
JP5753626B2 (ja) 2011-04-26 2015-07-22 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ピラゾリジン−3−オン誘導体
US10533000B2 (en) 2011-05-26 2020-01-14 Sunovion Pharmaceuticals, Inc. Metabotrophic glutamate receptor 5 modulators and methods of use thereof
US20130123254A1 (en) 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
UA110995C2 (uk) 2011-10-07 2016-03-10 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як модулятори метаботропного глутаматного рецептора
UA110862C2 (uk) 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
RS55313B1 (sr) 2012-07-17 2017-03-31 Hoffmann La Roche Ariletinil derivati
KR20150070102A (ko) 2012-10-18 2015-06-24 에프. 호프만-라 로슈 아게 mGluR5 수용체 활성의 조절제로서 에틴일 유도체
MY170152A (en) 2012-10-18 2019-07-09 Hoffmann La Roche Ethynyl derivative as modulators of mglur5 receptor activity
WO2014124560A1 (en) 2013-02-18 2014-08-21 Hua Medicine (Shanghai) Ltd. Mglur regulators
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
EA029352B1 (ru) * 2013-09-25 2018-03-30 Ф. Хоффманн-Ля Рош Аг Производные этинила
TWI649310B (zh) * 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 乙炔基衍生物
CA2939572A1 (en) 2014-02-19 2015-08-27 Jody Berry Marburg monoclonal antibodies
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
EP3110802B1 (en) 2014-02-25 2018-10-10 F. Hoffmann-La Roche AG Ethynyl derivatives
SG11201702606TA (en) 2014-10-03 2017-04-27 Massachusetts Inst Technology Antibodies that bind ebola glycoprotein and uses thereof
EP3271353B1 (en) 2015-03-19 2019-11-27 H. Hoffnabb-La Roche Ag 3-(4-ethynylphenyl)hexahydropyrimidin-2,4-dione derivatives as modulators of mglur4
MX374409B (es) 2015-07-15 2025-03-04 Hoffmann La Roche Derivados de etinilo como moduladores del receptor de glutamato metabotrópico.
MA45665B1 (fr) 2016-07-18 2020-11-30 Hoffmann La Roche Dérivés d'éthynyle

Also Published As

Publication number Publication date
RU2018103944A (ru) 2019-08-16
AR105341A1 (es) 2017-09-27
BR112017023084A2 (pt) 2018-07-10
MA42442B1 (fr) 2019-07-31
IL255096A0 (en) 2017-12-31
EP3322701B1 (en) 2019-05-01
US20190119290A1 (en) 2019-04-25
CO2017011174A2 (es) 2018-01-31
ES2733468T3 (es) 2019-11-29
TWI612962B (zh) 2018-02-01
IL255096B (en) 2020-01-30
PT3322701T (pt) 2019-06-28
CR20180022A (es) 2018-02-26
TR201909160T4 (tr) 2019-07-22
HUE045145T2 (hu) 2019-12-30
US20210269452A1 (en) 2021-09-02
LT3322701T (lt) 2019-07-10
CN107580598A (zh) 2018-01-12
UA120463C2 (uk) 2019-12-10
AU2016292863A1 (en) 2017-11-02
AU2016292863B2 (en) 2020-03-05
HRP20191139T1 (hr) 2019-09-20
EP3322701A1 (en) 2018-05-23
MX2018000592A (es) 2018-04-24
US10189848B2 (en) 2019-01-29
DK3322701T3 (da) 2019-07-08
RU2721776C9 (ru) 2020-10-22
US12006323B2 (en) 2024-06-11
US11034699B2 (en) 2021-06-15
CA2984711A1 (en) 2017-01-19
CL2018000036A1 (es) 2018-06-29
PL3322701T3 (pl) 2019-09-30
PH12018500106A1 (en) 2018-07-23
RS58929B1 (sr) 2019-08-30
MA42442A (fr) 2018-05-23
JP6761821B2 (ja) 2020-09-30
SI3322701T1 (sl) 2019-08-30
MX374409B (es) 2025-03-04
TW201707705A (zh) 2017-03-01
KR20180026438A (ko) 2018-03-12
CA2984711C (en) 2023-08-29
WO2017009275A1 (en) 2017-01-19
PE20180356A1 (es) 2018-02-21
RU2721776C2 (ru) 2020-05-22
JP2018524305A (ja) 2018-08-30
US20180134721A1 (en) 2018-05-17
CN107580598B (zh) 2020-11-13

Similar Documents

Publication Publication Date Title
BR112017027479A2 (ru)
RU2018103944A3 (ru)
BR112018004046A2 (ru)
BR112018004316A2 (ru)
BE2015C047I2 (ru)
CN303069424S (ru)
BR0002402B1 (ru)
BR0003401B1 (ru)
BR0003208B1 (ru)
BR0003189B1 (ru)
BR0003166B1 (ru)
BR0002874B1 (ru)
BR0002802B1 (ru)
BR0002694B1 (ru)
CN303074388S (ru)
BR0003686B1 (ru)
CN303073308S (ru)
CN303071480S (ru)
BR0009649B1 (ru)
CN303070285S (ru)
CN303068841S (ru)
BR0002033B1 (ru)
BR0001810B1 (ru)
CN303069653S (ru)
BR0009349B1 (ru)

Legal Events

Date Code Title Description
TK4A Correction to the publication in the bulletin (patent)

Free format text: CORRECTION TO CHAPTER -FG4A- IN JOURNAL 15-2020 FOR INID CODE(S) (72)

TH4A Reissue of patent specification